You are here

Vaccines

Primary tabs

Information on vaccines to counter Ebola and other diseases

The Mission of this group is to follow the development of vaccines and other medications to counter Ebola and other diseases.

Members

Kathy Gilbeaux mdmcdonald MDMcDonald_me_com mike kraft

Email address for group

vaccines_global@m.resiliencesystem.org

Experimental Ebola drug shelved; study explores virus clearance

CENTER FOR INFECTIOUS DISEASE POLICY AND RESEARCH by Lisa Schnirring     July 20, 2015

Tekmira Pharmaceuticals  announced that it has suspended development of TKM-Ebola, a drug cocktail that showed disappointing human trial results in West Africa, as a convalescent plasma trial at a Doctors Without Borders (MSF) facility in Guinea proceeded with no ill effects in patients so far...

In suspending TKM-Ebola development, the company said that a joint reevaluation of its contract with the US Department of Defense is under way.

In another development, MSF said a convalescent serum trial at its facility in Nongo, Guinea, has enrolled 101 people over the last few months, with no ill effects reported so far, according to a Jul 17 update on the outbreak. Patients at the Nongo treatment unit have the option to receive plasma donated by Ebola survivors....

Meanwhile, detailed testing at a Swiss hospital on a 43-year-old doctor infected with Ebola in Sierra Leone found that viral decay occurred in two phases, once starting 72 hours after symptom onset before any antiviral interventions, with acceleration in viral load decay after ZMAb infusion and oral favipiravir treatments began..

Read complete article.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Vaccine trial won’t cause Ebola - WHO

GRAPHIC ONLINE by Rebecca Quisacde-Duho and Rhodaline Oppong                              June 20, 2015

Rebecca Quaicoe-Duho & Rhodaline Oppong
Rebecca Quaicoe-Duho & Rhodaline Oppong
Rebecca Quaicoe-Duho & Rhodaline Oppong
Rebecca Quaicoe-Duho & Rhodaline Oppong

The World Health Organisation (WHO) has assured Ghanaians that the proposed Ebola vaccine trial will not cause Ebola in the country.

WHO says it views the safety of people as paramount and would, therefore, not overlook any wrongdoing in the development of a vaccine.

 The WHO Country Representative, Dr Magda Robalo, gave the assurance at a public sensitisation forum in Accra last Thursday....

 Recently, following public agitations, the Minister of Health, Mr Alex Segbefia, called for more consultation on the proposed Ebola vaccine trial which was to be undertaken at Hohoe in the Volta Region.

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Trial of Canadian Ebola drug stopped; no overall benefit shown

CANADIAN PRESS  by  Helen Branswell                       June 19, 2015

TORONTO -- A Canadian company that had been developing an Ebola drug says a clinical trial of the experimental product has been stopped.

Tekmira Pharmaceuticals says the trial was halted because it seemed clear that continuing was not likely to show that the drug works.

The drug is called TKM-Ebola. It was being tested with Ebola patients in Sierra Leone.

Read complete story.
http://www.ctvnews.ca/health/trial-of-canadian-ebola-drug-stopped-no-overall-benefit-shown-1.2430501

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Sierra Leone: Mothers Refuse to Vaccinate Children for Fear of Resurgent Ebola

BREITBART.COM  by Frances Martel                                             June 16, 2015

Doctors in Port Loko, a northwestern region of Sierra Leone outside Freetown, are reporting a significant drop in the number of mothers bringing their children to hospitals for routine vaccinations. The mothers, they say, fear exposing their children to a resurgent Ebola virus, and in keeping them from hospitals are risking triggering the spread of polio or measles.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Ebola vaccines in limbo expose need for more speed in trials

REUTERS by Kate Keller and Ben Hirschler                                      June 17, 2015

LONDON --Drugmakers' plans to conduct vast clinical trials to test and hopefully validate the first Ebola vaccines have been thwarted by success in beating back the deadly epidemic in West Africa.

GlaxoSmithKline, Merck and Johnson & Johnson are struggling to recruit volunteers with enough exposure to the disease to prove whether their vaccines are doing the job and preventing infection.

The story might have been very different with just another three or four months of disease spread, underscoring the need to act more quickly to develop vaccines for emerging diseases....

Guinea, where Ebola is still infecting new victims, as "the only hope" for showing efficacy, according to Kieny and to Adrian Hill, director of the Jenner Institute at Britain's Oxford University.

The WHO is overseeing the so-called ring vaccination study in Guinea in which close contacts and family around each new case of Ebola are vaccinated -- either immediately or after a three-week delay -- to see if the shot offers protection.

Read complete story.

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Favipiravir—a prophylactic treatment for Ebola contacts?

THE LANCET byMichel Van Herp, Hilde Declerck and Tom Decroo June 13, 2015

.. the efficacy of candidate Ebola vaccines for primary prevention has not been proven.2 Furthermore, in communities in which Ebola transmission might be ongoing, an important question is: how will such a vaccination be perceived if a vaccinated person develops Ebola? Such a scenario is possible in people who contract Ebola virus before vaccination. If a person is infected with Ebola virus before vaccination, the vaccine might have a post-exposure prophylactic effect. However, how effective this prophylaxis might be is unknown.2 Moreover, if someone is infected more than 48 h before vaccination, the post-exposure prophylactic effect is likely to be insufficient, leading to possible development of Ebola after vaccination. This scenario is likely to result in serious issues relating to community trust and acceptance of an Ebola vaccine.3 How to exclude Ebola among people presenting with post-vaccination fever is also an issue.2

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

How close is the Ebola vaccine?

PUBLIC BROADCASTING CORP by Caleb Hellerman         June 11, 2015

The quest for an Ebola vaccine has been a journey filled with excruciating delays and mad dashes. The latest outbreak in West Africa caused governments and drug companies to jumpstart research that had languished back when the threat of Ebola wasn’t big enough to sustain a commercial market. (Prior to 2013, the virus had sickened fewer than 2,300 people in known history). Human safety trials of two vaccines began last summer — each being given to a small group of healthy volunteers. When no major side effects were apparent, health officials scrambled to launch larger tests in the countries that were most affected by Ebola.

A volunteer receives an Ebola vaccine in Sierra Leone. Thousands of these voluntary immunizations have been tested so far in the West African nation. Photo by Cameron Hickey.

Problem, Solution, SitRep, or ?: 

A Chinese Ebola Drug Raises Hopes, and Rancor

NEW YORK TIMES   by Sheri Fink, MD                                                      June 12, 2015   

After a nurse who contracted Ebola in Sierra Leone was discharged Wednesday from a Rome hospital, a doctor there described the experimental treatments the patient had received as “absolutely miraculous.”

The lab at Beijing Mabworks, which developed the experimental drug, MIL77, used to treat Ebola. Credit Adam Dean for The New York Times

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Ghana halts Ebola vaccine trial due to community protests

REUTERS                                             June 10, 2015

ACCRA - Ghana has halted a plan to test two Ebola vaccines in an eastern town after legislators backed local protests against the trials sparked by fears of contamination, officials said on Wednesday.

The country's Food and Drugs Authority said it had begun enlisting volunteers in Hohoe in the Volta region to be injected with drugs made by Johnson & Johnson and Bavarian Nordic as part of a global Ebola vaccine drive.

Youth leaders threatened to boycott the program. "We don't want to be guinea pigs," one local leader told Reuters.

The (health) minister has suspended the trials indefinitely because the people said they don't want it," Health Ministry spokesman Tony Goodman said.

Read complete article.

http://news.yahoo.com/ghana-halts-ebola-vaccine-trial-due-community-protests-230206801--finance.html;_ylt=AwrC1Cj8y3hVjHUAonXQtDMD;_ylu=X3oDMTByOHZyb21tBGNvbG8DYmYxBHBvcwMxBHZ0aWQDBHNlYwNzcg--

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

NIH Study Finds No Evidence of Accelerated Ebola Virus Evolution in West Africa

NIH Institute of Allergy and Infectious Diseases (NIAID)                            June 9, 2015

According to a recent report from the National Institutes of Health (NIH), the current strain of the Ebola virus that is circulating through West Africa is called the Makona strain and is less aggressive than the original Mayinga strain that, which was isolated in Central Africa in 1976.
When compared to the Mayinga strain, the Makona strain takes approximately two additional days to start terminal disease in an animal subject. This is an important discovery to scientists, as they wonder whether the Ebola strain in West Africa will grow more severe over time.

The test subjects were cynomolgus macaques. Researchers used these animals to model disease and infection in humans. The scientists infected three macaques with the Mayinga strain from 1976 and an additional three with the Makona strain from 2015.

 
 Ebola virus, isolated in November 2014 from patient blood samples obtained in Mali. The virus was isolated on Vero cells in a BSL-4 suite at Rocky Mountain Laboratories.
Credit: NIAID RML

Read complete story.

Problem, Solution, SitRep, or ?: 

Pages

howdy folks
Page loaded in 0.846 seconds.